Vaxart, Inc. (VXRT) Operating Margin
- Operating margin · 12 months: Value 16.30%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 16.30% | Operating income / revenue. Period ending 2026-06-30. $39.61M ÷ $243.06M × 100 ≈ 16.30% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 39.61M USD | Operating Income (Loss) |
| Revenue | 243.06M USD | |
| Cost of products and services | (m) | |
| Research and development | 184.26M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $39.61M | $243.06M | (m) | $184.26M | (m) | 16.30% |
| 2026-03-31 | $38.18M | $255.61M | (m) | $200.25M | (m) | 14.94% |
| 2025-12-31 | $18.07M | $237.26M | (m) | $201.58M | (m) | 7.62% |
| 2025-09-30 | $-48.84M | $148.20M | (m) | $179.08M | (m) | -32.96% |
| 2025-06-30 | $-55.51M | $80.72M | (m) | $118.20M | (m) | -68.76% |
| 2025-03-31 | $-57.16M | $47.40M | (m) | $85.94M | (m) | -120.60% |
| 2024-12-31 | $-66.29M | $28.70M | (m) | $74.21M | (m) | -230.99% |
| 2024-09-30 | $-71.70M | (m) | (m) | $66.26M | (m) | (m) |
| 2024-06-30 | $-75.05M | (m) | (m) | $66.20M | (m) | (m) |
| 2024-03-31 | $-81.84M | (m) | (m) | $67.53M | (m) | (m) |
| 2023-12-31 | $-83.35M | (m) | (m) | $68.14M | (m) | (m) |
| 2023-09-30 | $-97.58M | (m) | (m) | $73.90M | (m) | (m) |
| 2023-06-30 | $-109.19M | (m) | (m) | $81.36M | (m) | (m) |
| 2023-03-31 | $-115.38M | (m) | (m) | $82.47M | (m) | (m) |
| 2022-12-31 | $-114.59M | (m) | (m) | $81.05M | (m) | (m) |
| 2022-09-30 | $-107.66M | (m) | (m) | $76.13M | (m) | (m) |
| 2022-06-30 | $-95.49M | (m) | (m) | $66.07M | (m) | (m) |
| 2022-03-31 | $-82.02M | (m) | (m) | $56.88M | (m) | (m) |
| 2021-12-31 | $-72.75M | (m) | (m) | $48.75M | (m) | (m) |
| 2021-09-30 | $-61.90M | (m) | (m) | $41.81M | (m) | (m) |
| 2021-06-30 | $-52.24M | (m) | (m) | $34.02M | (m) | (m) |
| 2021-03-31 | $-44.99M | (m) | (m) | $28.39M | (m) | (m) |
| 2020-12-31 | $-30.17M | (m) | (m) | $19.86M | (m) | (m) |
| 2020-09-30 | $-22.43M | (m) | (m) | $14.56M | (m) | (m) |
| 2020-06-30 | $-19.56M | (m) | (m) | $13.66M | (m) | (m) |
| 2020-03-31 | $-16.03M | (m) | (m) | $12.25M | (m) | (m) |
| 2019-12-31 | $-15.79M | (m) | (m) | $14.54M | (m) | (m) |
| 2019-09-30 | $-14.35M | (m) | (m) | $15.72M | (m) | (m) |
| 2019-06-30 | $-15.51M | (m) | (m) | $16.39M | (m) | (m) |
| 2019-03-31 | $-18.29M | $8.06M | (m) | $17.70M | (m) | -226.83% |
| 2018-12-31 | $-21.76M | $4.16M | (m) | $17.27M | (m) | -523.11% |
| 2018-09-30 | $-20.47M | $5.09M | (m) | $15.30M | (m) | -402.00% |
| 2018-06-30 | $-19.59M | $4.91M | (m) | $13.72M | (m) | -398.90% |
| 2018-03-31 | $-17.41M | $4.40M | (m) | $12.41M | (m) | -395.53% |
| 2017-12-31 | $-17.20M | $7.80M | (m) | $15.80M | (m) | -220.51% |
| 2017-09-30 | $-22.90M | $8.90M | (m) | $23.50M | (m) | -257.30% |
| 2017-06-30 | $-27.50M | $8.90M | (m) | $28.30M | (m) | -308.99% |
| 2017-03-31 | $-28.60M | $9.30M | (m) | $30.50M | (m) | -307.53% |
| 2016-12-31 | $-30.10M | $9.80M | (m) | $32.30M | (m) | -307.14% |
| 2016-09-30 | $-28.10M | $7.70M | (m) | $28.40M | (m) | -364.94% |
| 2016-06-30 | $-25.20M | $9.30M | (m) | $26.30M | (m) | -270.97% |
| 2016-03-31 | $-38.50M | $12.90M | (m) | $25.70M | (m) | -298.45% |
| 2015-12-31 | $-32.20M | $13.40M | (m) | $21.90M | (m) | -240.30% |
| 2015-09-30 | $-19.20M | $25.60M | (m) | $20.40M | (m) | -75.00% |
| 2015-06-30 | $-19.50M | $24.60M | (m) | $19.80M | (m) | -79.27% |
| 2015-03-31 | $-10.00M | $28.90M | (m) | $20.70M | (m) | -34.60% |
| 2014-12-31 | $-7.90M | $52.50M | (m) | $20.10M | (m) | -15.05% |
| 2014-09-30 | $-14.40M | $57.10M | (m) | $19.40M | (m) | -25.22% |
| 2014-06-30 | $-11.50M | $68.70M | (m) | $17.50M | (m) | -16.74% |
| 2014-03-31 | $-7.40M | $69.60M | (m) | $16.90M | (m) | -10.63% |
| 2013-12-31 | $-10.60M | $52.60M | (m) | $17.20M | (m) | -20.15% |
| 2013-09-30 | $-18.40M | $44.40M | (m) | $17.60M | (m) | -41.44% |
| 2013-06-30 | $-22.10M | $33.60M | (m) | $19.20M | (m) | -65.77% |
| 2013-03-31 | $-14.79M | $24.14M | (m) | $13.46M | (m) | -61.25% |
| 2012-12-31 | $-16.98M | $12.28M | (m) | $10.04M | (m) | -138.27% |
| 2012-09-30 | $-11.16M | $2.73M | (m) | $7.58M | (m) | -408.97% |
| 2012-06-30 | $-11.98M | $3.18M | (m) | $8.82M | (m) | -376.38% |
| 2012-03-31 | $-13.80M | $6.30M | (m) | $13.95M | (m) | -219.09% |
| 2011-12-31 | $-9.76M | $14.84M | (m) | $17.77M | (m) | -65.79% |
| 2011-09-24 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $-30.50M | $12.50M | (m) | $33.50M | (m) | -244.00% |
| 2011-06-25 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-26 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-25 | $-1.20M | $35.01M | (m) | $26.08M | (m) | -3.42% |
| 2010-09-25 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-26 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-26 | $-17.98M | $10.49M | (m) | $16.49M | (m) | -171.38% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |